Prognostic significance of CIP2A expression in solid tumors: A meta-analysis

Tang, Min; Shen, Jiaofeng; Li, Ping; Zhou, Li-Na; Zeng, Ping; Cui, Xueying; Chen, Min-Bin; Tian, Ye

doi:10.1371/journal.pone.0199675

Cited by 14 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, upregulation was significantly associated with features of poor prognosis, such as the large tumor size, cervical lymph node involvement, undifferentiated tumors, and advanced clinical stage. Our observations were verified in OSCC [27], NPC [28], breast [31], non-small cell lung cancer (NSCLC) [34], and many other malignancies [35].…”

Section: Discussionsupporting

confidence: 60%

Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

Cancerous inhibitor of protein phosphatase 2A (CIP2A) has been identified as one of the most commonly altered proteins in human cancers. It blocks the tumor-suppressive action of protein phosphatase 2A (PP2A) complex and enhances malignancy. Thirty-five patients with squamous cell carcinoma of the oral cavity underwent surgical resection of the tumor. CIP2A was assessed by quantitative real-time PCR in the resected tumor tissues and in their adjacent normal tissues. CIP2A was found to be overexpressed in all oral squamous cell carcinoma (OSCC) specimens in comparison to their surrounding normal tissue. CIP2A overexpression was statistically correlated with poor prognostic feature of the tumor. Thus, a high expression level of CIP2A was associated with shorter survival. In conclusion, CIP2A is upregulated in OSCC, and its overexpression is correlated with aggressiveness of the tumor and poor outcome and survival. It may serve as a prognostic marker of OSCC.

show abstract

Section: Discussionsupporting

confidence: 60%

Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence indicates that CIP2A overexpression is associated with poor survival in patients with solid tumors and may serve as a predictive factor of poor prognosis. 10,15,25 Preclinical in vitro and in vivo studies have shown that CIP2A may regulate the proliferation, senescence, and apoptosis of multiple cancer cells [26][27][28] and contribute to resistance to chemotherapy such as cisplatin or docetaxel in solid tumors. [29][30][31] Therefore, CIP2A inhibition may serve as a promising modality to overcome chemoresistance.…”

Section: Discussionmentioning

confidence: 99%

The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation

et al. 2019

View full text Add to dashboard Cite

Background CIP2A may activate multiple oncogenic proteins and promote the proliferation of various cancer cells. Methods We investigated that the role of CIP2A in radioresistant head and neck cancer (HNC) cell line with TP53 mutation and the effect of the rapamycin on the response of HN31 with TP53 mutation cells to irradiation related to CIP2A expression. Results CIP2A expression was stimulated by p53 mutation and critical for the inhibition of senescence induction in response to radiation. The treatment with radiation alone neither induced cytotoxicity in HN31 cells nor completely suppressed the activation of CIP2A. However, the combination of radiation and rapamycin increase the radiosensitivity through the induction of senescence with downregulation of CIP2A expression both in vivo and in vitro. Conclusion Our results suggest that CIP2A may serve as a therapeutic target of rapamycin through induction of senescence in radioresistant HNC with TP53 mutation.

show abstract

“…The prognostic value for CIP2A, a direct inhibitor of a tumour suppressor PP2A, has been reported in wide range of human solid tumours (14); however, its association with human leukaemia has not yet been clarified. To assess the expression level of CIP2A and its downstream target PP2A in AML and also to explore its plausible contributory role in leukomogensis, peripheral blood of 30 AML patients (56% male and 44% female) with the median age of 49 years old were collected for quantitative real-time PCR analysis.…”

Section: The Expression Level Of Cip2a and Pp2a In Aml Samplesmentioning

confidence: 99%

Contribution Value of Akt, c-Myc, CIP2A, and PP2A Genes Expression in Leukemogenesis: A Bright Perspective on the Molecular Pattern of Patients with Acute Myeloid Leukemia (AML)

et al. 2020

View full text Add to dashboard Cite

Background: The heterogeneous nature of acute myeloid leukemia (AML) and the hurdle to find a suitable treatment strategy for this malignancy put this type of leukemia at the top of the list of the priorities for finding a valuable biomarker to improve its treatment and predict the outcome of the patients. Objectives: Given the involvement of the variety of signaling pathways, foremost the PI3K axis in the pathogenesis of human cancers, we aimed to investigate the expression of the most important downstream targets of this pathway to propose a plausible mechanism underlying AML pathogenesis. Methods: In this case-control study, the blood samples from 30 patients diagnosed with AML were collected and after extracting their RNAs, the expression levels of Akt, c-Myc, CIP2A, and PP2A were evaluated using qRT-PCR analysis. For the control group, we also collected blood samples from 10 healthy volunteers. Afterward, by applying statistical analysis, we determined the probable correlation between the expressions of the aforementioned genes. Results: There was a significant elevation in the expression levels of Akt, c-Myc, and CIP2A coupled with the meaningful reduction in the expression level of PP2A in AML samples. However, we failed to find any significant association between the expression level of the indicated genes and age, sex, and the percentage of the blasts. Conclusions: As the most straightforward interpretation of our results, we propose that probably the association between PI3K and c-Myc which is built through the interaction between CIP2A and PP2A may play a pivotal role in the pathogenies of AML and any component of this axis could serve as a potential new target for more profound treatment strategy. However, further detailed investigations in this field are required to clarify the exact role of this interesting testis-specific pathway in the context of hematological malignancies, in particular AML.

show abstract

Prognostic significance of CIP2A expression in solid tumors: A meta-analysis

Cited by 14 publications

References 45 publications

Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma

Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma

The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation

Contribution Value of Akt, c-Myc, CIP2A, and PP2A Genes Expression in Leukemogenesis: A Bright Perspective on the Molecular Pattern of Patients with Acute Myeloid Leukemia (AML)

Contact Info

Product

Resources

About